Additional file 2 of Characterization of tumor microenvironment and tumor immunology based on the double-stranded RNA-binding protein related genes in cervical cancer

Additional file 2: Table S1. 35 dsRBPs colected and applied in current study. Table S2. Clinical characteristics of cervical cancer samples within different dsRBP clusters. Table S3. List of dsRBP cluster-associated DEGs. Table S4. List of prognostic dsRBP cluster-associated DEGs. Table S5. List of further achieved prognostic dsRBP cluster-associated DEGs after multistep filtering. Table S6. performance of signature in the TCGA-CESC cohort, GSE44001 cohort and CGCI-HTMCP-CC cohort. Table S7. Patients information stratified by the signature in the TCGA-CESC cohort. Table S8. Clinical feature information of the high- and low-risk group. Table S9. Sample information stratified by the signature in the GSE44001 validation cohort. Table S10. Sample information stratified by the signature in the CGCI-HTMCP-CC validation cohort. Table S11. Differentially expressed genes between Scissor+ and Scissor− cells.

附加文件2：表S1。本研究收集并应用的35种双链RNA结合蛋白（double-stranded RNA-binding protein, dsRBP）。
表S2。不同双链RNA结合蛋白簇内宫颈癌样本的临床特征。
表S3。双链RNA结合蛋白簇相关差异表达基因（differentially expressed gene, DEG）列表。
表S4。与预后相关的双链RNA结合蛋白簇关联差异表达基因列表。
表S5。经多步筛选后进一步获得的预后相关双链RNA结合蛋白簇关联差异表达基因列表。
表S6。该特征模型在TCGA-CESC队列、GSE44001队列及CGCI-HTMCP-CC队列中的表现性能。
表S7。TCGA-CESC队列中按该特征模型分层的患者信息。
表S8。高风险组与低风险组的临床特征信息。
表S9。GSE44001验证队列中按该特征模型分层的样本信息。
表S10。CGCI-HTMCP-CC验证队列中按该特征模型分层的样本信息。
表S11。Scissor+细胞与Scissor−细胞之间的差异表达基因。